Lirilumab

立即咨询

Lirilumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1000676-41-4

IPH2102

Lirilumab (IPH2102) 是一种anti-KIR单克隆抗体，其具有抗肿瘤活性。Lirilumab 可用于白血病、头颈部鳞状细胞癌 (SCCHN) 的研究。

生物活性

Lirilumab (IPH2102) is ananti-KIRmonoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research^[1]^[2].

体内研究
(In Vivo)

Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor^[2].

Animal Model:	Rag1KO-Tg KIR mice injected with tumor cells^[2]
Dosage:	15 mg/kg
Administration:	intravenous injection; 15 mg/kg; once
Result:	Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.

Clinical Trial

CAS 号

1000676-41-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.